Stifel Sticks With Buy on Glaukos, Cites Momentum for iDose and Epioxa
Stifel has maintained a Buy rating and a $160 per-share price target on Glaukos (GKOS), citing encouraging signs for the company’s iDose and Epioxa programs. The firm expects sequential expansion in iDose volumes in early 2026 and reports Epioxa system placements running ahead of management targets. Recent regulatory and payer developments, plus ba…